Similar articles

• Antifactor Xa activity and antithrombotic activity in rats of structural analogues of the minimum antithrombin III binding sequence: discovery of compounds with a longer duration of action than of the natural pentasaccharide.

  Meuleman DG, Hobbelen PM, Van Dinther TG, Vogel GM, Van Boeckel CA, Moelker HC. Meuleman DG, et al. Semin Thromb Hemost. 1991;17 Suppl 1:112-7. Semin Thromb Hemost. 1991. PMID: 2068564
• Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.

  Hérault JP, Bernat A, Gaich C, Herbert M. Hérault JP, et al. Thromb Haemost. 2002 Feb;87(2):238-44. Thromb Haemost. 2002. PMID: 11858483
• Biologic studies on chemically synthesized pentasaccharide and tetrasaccharide fragments.

  Choay J. Choay J. Semin Thromb Hemost. 1985 Apr;11(2):81-5. doi: 10.1055/s-2007-1004362. Semin Thromb Hemost. 1985. PMID: 4035368
• From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile.

  Petitou M, Nancy-Portebois V, Dubreucq G, Motte V, Meuleman D, de Kort M, van Boeckel CA, Vogel GM, Wisse JA. Petitou M, et al. Thromb Haemost. 2009 Nov;102(5):804-10. doi: 10.1160/TH09-01-0063. Thromb Haemost. 2009. PMID: 19888512 Review.
• Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide.

  Walenga JM, Jeske WP, Bara L, Samama MM, Fareed J. Walenga JM, et al. Thromb Res. 1997 Apr 1;86(1):1-36. doi: 10.1016/s0049-3848(97)00042-x. Thromb Res. 1997. PMID: 9172284 Review. No abstract available.